350 руб
Журнал «Вопросы биологической, медицинской и фармацевтической химии» №6 за 2013 г.
Статья в номере:
Новые противотуберкулёзные препараты и терапии
Ключевые слова: туберкулёз туберкулёз с множественной лекарственной устойчивостью туберкулёз с широкой лекарственной устойчивостью новые препараты фторхинолоны нитроимидазолы линезолид
Авторы:
А. Карчевская - студент 5-го курса, кафедра биоорганической химии, биологический факультет, Московский государственный университет им. М.В. Ломоносова
Аннотация:
Обзор посвящен последним разработкам противотуберкулёзных препаратов и новых способов лечения, а именно созданию новых комбинаций препаратов. Рассмотрены различные препараты, их механизмы действия.
Страницы: 20-23
Список источников

  1. O-Grady J., Maeurer M., Mwaba P. et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr. Opin. Pulm. Med. 2011. V. 17. P. 134-141.
  2. Jeon C., Harries A., Baker M. et al. Bi-directional screening for tuberculosis and diabetes: a systematic review // Tropical Medicine and International Health. 2010. V. 15. P. 1300-1314.
  3. Zumla A., Raviglione M., Hafner R. et al. Tuberculosis // N. Engl. J. Med. 2013. V. 368. P. 745-55.
  4. Chang K., Yew W., Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses // Antimicrobial Agents and Chemotherapy. 2011. V. 55. P. 4449-4505.
  5. Lienhardt C., Glaziou P., Uplekar M. et al. Global tuberculosis control: lessons learnt and future prospects. Nature reviews. Microbiology. 2012. V. 10. P. 407-416.
  6. Minion J., Pai M. Bacteriophage assays for rifampicin resistance detection in Mycobacterium tuberculosis: updated meta-analysis // Int. J. Tuberc. Lung. Dis. 2010. V. 14. № 8. P. 941-951.
  7. Gaminero J., Sotgiu G., Zumla A. et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis // Lancet Infect. Dis. 2010. V. 10. 621-629.
  8. World health organization global tuberculosis report. 2012. ISBN 978 92 4 156450 2.
  9. Pai M., Minion J., Sohn H. et al. Novel and improved technologies for tuberculosis diagnosis: progress and challenges // Clin. Chest. Med. 2009. V. 30. P. 701-716.
  10. Lienhardt C., Vernon A., Raviglione M. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes // Curr. Poin. Pulm. Med. 2010. V. 16. V. 186-193.
  11. Chen H., Yu M., Huang W. et al. Molecular detection of rifabutin-susceptibleMycobacterium tuberculosis // J. Clin. Microbiol. 2012. V. 50. № 6. P. 2085-2088.
  12. Baciewicz A., Chrisman C., Finch C. et al. Update on rifampin and rifabutin drug interactions // Arch. Intern. Med. 2002. V. 162. P. 126-136.
  13. Sterling T., Villarino M., Borisov A. et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection // N. Engl. J. Med. 2011. V. 365. № 23. P. 2155-2166.
  14. Dorman S., Goldberg S., Stout J. et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium // JID. 2012. V. 206. № 7. P. 1030-40.
  15. Zaunbrecher M., Sikes R., Metchock B. et al.Overexpression of the chromosomally encoded aminoglycoside acetyltransferaseeis confers kanamycin resistance in Mycobacterium tuberculosis // PNAS. 2009. V. 106. № 47. P. 20004-20009.
  16. Sugawara I., Zhang J., Li C. Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin // Indian Journal of experimental biology. 2009. V. 47. № 6. 520-522.
  17. Amikacin // Tuberculosis. 2008. V. 88. № 2. P. 87-88.
  18. Engstrcm A., Perskvist N., Werngren J. et al. Comparison of clinical isolates and in vitroselected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis // J. Antimicrob. Chemother. 2011. V. 66. № 6. P. 1247-1254.
  19. Ajbani K., Rodrigues C., Shenai S. et al. Mutation and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India // J. Clin. Microbiol. 2011. V. 49. № 4. P. 1588-1590.
  20. Chakravorty S., Aladegbami B., Thoms K. et al. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in real-time PCR assay // J. Clin. Microbiol. 2011. V. 49. № 3. 932-940.
  21. Devasia R., Blackman A., Eden S. et al. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoruquinolone susceptibility // J. Clin. Microbiol. 2012. V. 50. № 4. P. 1390-1396.
  22. Piton J., Petrella S., Delarue M. et al. Stryctural insights into the quinolone resistance mechanism of Mycobacterium tuberculosisDNA gyrase // PLoS ONE. 2010. V. 5. № 8. P. 12245.
  23. Lienhardt C., Raviglione M., Spigelman M. et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future // The Journal of Infectious Diseases. 2012. V. 205. Suppl 2. P. 241-249.
  24. Veziris N., Ibrahim M., Lounis N. et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis // PLoS ONE. 2011. V. 6. № 3. P. 17556.
  25. Sarkar S., Suresh M. An overview of tuberculosis chemotherapy - a literature review // J. Pharm. Pharmaceut. Sci. 2011. V. 14. № 2. P. 148-161.
  26. Haagsma A., Abdillahi-Ibrahim R., Wagner M. et al. Selectivity of TMC207 towards mycobacterial ATPsynthase compared with that towards eukaryotic homologue // Antimicrobial agents and chemotherapy. 2009. V. 53. № 3.P. 1290-1292.
  27. Tawari N., Bairwa R., Ray M. et al. Design, synthesis and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents // FEBS J. 2012. V. 279. № 1. P. 113-125.
  28. Coban A., Deveci A. Y. Cayci et al. In vitro effect of tigecycline against Mycobacterium tuberculosis and a review of the available drugs for tuberculosis // Afr. J. Microbiol. Res. 2011. V. 5. № 3. P. 311-315.
  29. Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683 a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice // PLoS Medicine. 2006. V. 3. № 11. P. 466.
  30. Shehzad A., Rehman G., Ul-Islam M. et al. Challenges in the development of drugs for the treatment of tuberculosis // Braz. J. Infect. Dis. 2013. V. 17. № 1. P. 74-81.
  31. Ginsberg A., Laurenzi M., Rouse D. et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects // Antimicrob. Agents. Chemother. 2009. V. 53. № 9. P. 3720-3725.
  32. Goxon G., Craig D., Corrales R. et al. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues // PLoS ONE. 2013. V. 8. № 1. P. e53162.
  33. Diacon A., Dawson R., Hanekom M. et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients // Antimicrob. Agents. Chemother. 2010. V. 54. № 8. P. 3402-3407.
  34. Schecter G., Scott C., True L. et al. Linezolid in the treatment of multidrug-resistant tuberculosis // CID. 2010. V. 50. № 1. P. 49-55.
  35. Kaneko T., Cooper C., Mdluli K. Challenges and opportunities in developing novel drugs for TB // Future Med. Chem. 2011. V. 3. № 11. P. 1373-1400.
  36. Alfenaar J., van der Laan T., Simons S. et al.Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480 // Antimicrob. Agents. Chemother. 2011. V. 55. № 3. P. 1287-1289.
  37. Tahlan K., Wilson R., Kastrinsky D. et al. SQ109 targets MmpL3, a membrane transporter of trehalosemonomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. 2012. V. 56. № 4. P. 1797-809.